[TAVI: History and perspectives].

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Medical Device Technology

Background:

• Percutaneous aortic valve replacement, or TAVI, originated from an idea considered unconventional.
• Initial clinical development involved compassionate implantation phases.
• Large randomized trials like PARTNER and COREVALVE US were pivotal.

Observation:

• TAVI has become established in European and American guidelines for inoperable or high-surgical-risk patients.
• Recent studies (PARTNER 2, SURTAVI) demonstrate positive outcomes in intermediate-risk patients.
• Ongoing trials are evaluating TAVI in a broader patient population.

Findings:

• TAVI is increasingly recognized as a viable treatment option for aortic stenosis.
• Evidence supports TAVI's efficacy and safety in specific patient groups.
• Clinical adoption is driven by robust data from major trials.

Implications:

• Future European guidelines are expected to include TAVI for intermediate-risk patients.
• TAVI is poised to become the standard treatment for most patients with aortic stenosis.
• Continued research will likely expand TAVI's role in cardiovascular care.